Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence.
Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. · 2018
Read Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. by Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5964069.txt.
Introduction
Vera-Ramirez and co-authors show that autophagy keeps dormant breast cancer cells alive and feeds later recurrence. Their study appeared in Nature Communications. Breast cancer often returns years after treatment. The relapse grows from dormant tumour cells that spread early. How those cells survive their long quiet phase was largely unknown. The team tested autophagy in mouse and human dormancy models.
Blocking autophagy cut dormant cell survival sharply, they report. Metastatic burden fell as well in their models. The gene ATG7 proved essential for switching autophagy on. Blocking the flow left damaged mitochondria to pile up. Reactive oxygen species then rose and drove cell death.
Catalog record
| CREATOR | Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence By Laura Vera-Ramirez, Suman K Vodnala, Ryan Nini, Kent W Hunter, Jeffrey E Green Published in: Nature Communications DOI: 10.1038/s41467-018-04070-6 ABSTRACT Abstract Cancer recurrence after initial diagnosis and treatment is a major cause of breast cancer (BC) mortality, which results from the metastatic outbreak of dormant tumour cells. Alterations in the tumour microenvironment can trigger signalling pathways in dormant cells leading to their proliferation. However, processes involved in the initial and the long-term survival of disseminated dormant BC cells remain largely unknown. Here we show that autophagy is a critical mechanism for the survival of disseminated dormant BC cells. Pharmacologic or genetic inhibition of autophagy in dormant BC cells results in significantly decreased cell survival and metastatic burden in mouse and human 3D in vitro and in vivo preclinical models of dormancy. In vivo experiments identify autophagy gene autophagy-related 7 (ATG7) to be essential for autophagy activation. Mechanistically, inhibition of the autophagic flux in dormant BC cells leads to the accumulation of damaged mitochondria and reactive oxygen species (ROS), resulting in cell apoptosis. INTRODUCTION Ninety percent of BC-related deaths are due to metastatic disease1. Despite metastasis being the leading cause of BC-related mortality, the molecular mechanisms of metastatic progression remain poorly understood2. Although most patients do not present with overt metastases at diagnosis, a significant number succumb to disseminated disease years after the removal and treatment of the primary tumour. Disseminated tumour cells (DTCs) have frequently been observed at early stages of BC suggesting that late recurrence of BC may result from DTCs that have remained quiescent for decades3,4. Signals that trigger the outgrowth of dormant cancer cells remain largely unknown, although the tumour microenvironment plays a critical role in this process5–7. We previously developed and validated in vitro and in vivo model systems to study BC dormancy8–10. Briefly, the D2A1 and D2.0 R tumour cell lines (derived from murine mammary hyperplastic alveolar nodules11,12) form primary tumours when injected into the mammary fat pad of mice and disseminate to the lungs. D2A1 cells form macrometastases in the lungs within ~1–3 weeks. In contrast D2.0 R cells remain dormant at the metastatic site for about 4 months before forming relatively few lung metastases13. The 3D in vitro system has been shown to be predictive of the dormant or proliferative phenotype of several mouse and human BC cell lines8. D2.0 R and MCF-7 cells remain quiescent on basal membrane extract (BME) matrices for 12 days whereas the highly metastatic D2A1, MDA-MB-231 and 4T1 cells spontaneously outbreak into a proliferative state between day 1 and 6 of culture on BME8. These studies demonstrated that changes in the microenvironment, including exposure to collagen 1 (COL1) or fibronectin, induce the dormant-to-proliferative switch of D2.0 R cells8,10. In vivo studies are consistent with these in vitro findings, where lung fibrosis induced by the intranasal instillation of a transforming growth factor beta (TGFβ) expressing adenoviral vector drives the proliferative outbreak of otherwise dormant D2.0 R cells when seeded to the lungs by tail vein injection9. We have previously shown that the dormant-to-proliferative switch of D2.0 R cells requires the activation of integrin β1 receptor and downstream signalling through focal adhesion kinase (FAK), Src, ERK1/2 and myosin light chain kinase (MLCK) leading to actin stress fibre formation8,9. Moreover, the pharmacological inhibition of Src and MEK prevented the proliferative outbreak of dormant D2.0 R cells14 in vivo. Little is understood about the processes associated with the survival of disseminated dormant tumour cells. Although autophagy has been proposed as a potential mechanism promoting dormant cancer cell survival, few studies have addressed this experimentally15–18. Autophagy is an evolutionarily conserved mechanism of cell survival activated in response to metabolic stress to degrade organelles, misfolded proteins and portions of the cytosol to ensure proper energy balance under nutrient deprivation conditions and to recycle dysfunctional organelles and macromolecules19. In this study, we demonstrate that pharmacologic or genetic inhibition of autophagy greatly impairs the survival of dormant BC cells in vitro and in vivo, but has minimal effect on metastatic growth once dormant cells have transitioned to a proliferative state. Moreover, inhibition of autophagy results in the accumulation of damaged mitochondria and oxidative stress that drives apoptotic cell death. Inhibition of autophagy may therefore be a potential mechanism to eliminate dormant tumour cells and prevent recurrence of BC. RESULTS Solitary dormant tumour cells are autophagic To investigate the occurrence of autophagy in dormant breast tumour cells, we analysed the expression pattern of Microtubule-associated protein 1 A/1B-light chain 3 (MAP1LC3, also known as LC3) and Lysosomal-associated membrane protein 1 (LAMP1) over time in D2.0 R cells on BME (cells remain dormant) and BME plus COL1 matrices (which induces proliferation of the dormant cells)8 (Supplementary Fig. 1). Consistent with activation of autophagy, D2.0 R cells in BME showed increased expression of LAMP1 and LC3 over time. In contrast, D2.0 R cells in BME plus collagen 1 (COL1) exhibited much lower levels of LAMP1 and LC3 staining throughout the 8-day time course (Fig. 1a, b). Validation of autophagy in D2.0 R cells on BME was demonstrated using a tandem fluorescent-tagged LC3B reporter containing mCherry and EGFP (mCherry-EGFP-LC3) that allows real time monitoring of autophagic flux in live cells20 (Supplementary Fig. 2). Yellow LC3 puncta (early autophagosomes not yet fused with lysosomes) were detected in 81.25% of dormant D2.0 R cells at Day 5 of culture. This percentage dropped down to 3.12% at Day 8 (Fig. 1c, d), at which time 68.75% of dormant D2.0 R cells exhibited red-only fluorescent puncta (mature autolysosomes) (Fig. 1c). We conclude that the non-proliferating BC cells are autophagic while in a dormant state. [Figure: D2.0 R cells activate autophagy upon entering a dormant state. Representative images are shown for a Immunofluorescent staining of lysosomal (LAMP1, red) and autophagic (LC3, green) markers of D2.0 R cells in BME (upper panels) and BME + COL1 (lower panels) with b Quantification of the percentage of cells exhibiting LC3 positive puncta and LAMP1 staining out of the total number of cells analysed (mean ± s.e.m, n = 30–42 cells. Comparisons are relative to Day 1 by Kruskal–Wallis, Dunn’s post test. *P ≤ 0.05; ****P ≤ 0.0001) and the average number of LC3 puncta per cell (Comparisons by Kruskal–Wallis, Dunn’s post test. **P ≤ 0.01 and ****P ≤ 0.0001). c D2.0 R cells transfected with the mCherry-GFP-LC3 reporter show activation and completion of the autophagic cycle (red fluorescence only) when plated in BME matrices for 8 days. d The graphs represent the percentage of cells with double-positive puncta (mCherry+ and GFP+) (autophagosomes) out of the total number of cells analysed (left graph) (mean ± s.e.m, n = 35–39 cells). Comparisons by Kruskal–Wallis, Dunn’s post test. ****P ≤ 0.0001) and the rate of conversion from cells exhibiting yellow puncta to red-only puncta expressed as fold change (right graph). Scale bars are 50 and 10 μm for a and 20 and 10 μm for b] Autophagy inhibition decreases viability of dormant cells To test the functional importance of autophagy in BC dormancy, D2.0 R cells were seeded on BME and treated with 50 μM Hydroxychloroquine (HCQ), an inhibitor of autophagy21, (based upon a dose-response analysis; see Supplementary